Milestone Scientific (MLSS) reported Q1 results with narrower loss than expected.
Shares rose 8.8% in pre-market trading as investors focused on progress toward profitability.
Adjusted loss was -$0.01 per share, beating the -$0.02 consensus. Revenue of $2.16M missed the $2.35M estimate, down 3% YoY.
Revenue shortfall partly due to shipping challenges to the Middle East amid regional conflict.
Operating loss narrowed to $828K from $2.0M a year ago, a $1.2M improvement driven by over 30% expense reduction.
CEO Eric Hines: "We delivered meaningful improvements in operating efficiency."
Medical business revenue more than doubled YoY.
Company reaffirmed 2026 revenue outlook of $9.8M-$10.2M.
In April, a $2.15M financing was completed. Milestone targets cash flow breakeven in early 2027.
